West Pharmaceutical stock price target raised to $350 from $325 at KeyBanc

Investing.com - KeyBanc raised its price target on West Pharmaceutical (NYSE:WST) to $350 from $325 while maintaining an Overweight rating on the stock. The company, currently trading at $307.25 with a market capitalization of $22.1 billion, is trading above its InvestingPro Fair Value estimate.

The price target increase follows what KeyBanc described as a "top-to-bottom beat" for West Pharmaceutical, with the company showing approximately 9% organic growth in the third quarter, excluding incentives and CGM. The company maintains strong fundamentals with a gross profit margin of 35.27% and overall revenue growth of 2.9% in the last twelve months. InvestingPro analysis reveals 13 additional key insights about West Pharmaceutical’s performance and outlook.

KeyBanc noted that visibility is improving for West Pharmaceutical’s long-term growth plan of 7-9%, supported by new capacity ramping up in Dublin and early implementation of Annex-1 regulations.

The firm also highlighted West Pharmaceutical’s execution in margin improvement through drug handling and automation in its Proprietary Devices segment.

KeyBanc mentioned that Stevanato Group (NYSE:STVN), which reports on November 6, is set up conservatively for the third quarter with a 5.6% top-line growth estimate compared to West Pharmaceutical’s 5.1% (approximately 9% excluding one-off factors).

In other recent news, West Pharmaceutical Services Inc . reported its third-quarter earnings for 2025, surpassing market expectations. The company achieved an adjusted earnings per share (EPS) of $1.96, exceeding the forecasted $1.69, and reported revenue of $805 million, which was higher than the predicted $786.33 million. In addition, West Pharmaceutical raised its full-year revenue guidance to between $3.06 billion and $3.07 billion.

Analyst firms have responded positively to these developments. BofA Securities increased its price target for West Pharmaceutical to $370, maintaining a Buy rating, citing confidence in the company’s growth trajectory. Similarly, Evercore ISI raised its price target to $390 from $350, retaining an Outperform rating, and noted that their "bull thesis" is materializing as expected with the High-Value Product Components strategy. These recent developments reflect a strong outlook for West Pharmaceutical, as indicated by the revised earnings and analyst assessments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.